CTRI/2009/091/000729已完成2 期
A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non -Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent -Onset Type 1 Diabetes Mellitus.
MacroGenics Incorporated0 个研究点目标入组 538 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 538
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Subjects must meet all of the following criteria to participate in the extension study: Complete Protocol CP-MGA031-01 (i.e., all subjects who complete Study Day 728, regardless of how many doses of study drug are received).
- •2.Provide written informed consent. Written assent will be obtained for subjects under 18 years of age, according to applicable regulations. If possible, written informed consent and/or assent should be obtained for Protocol CP-MGA031-02 at the last visit in CP¬MGA031-01 . The investigator is to give the subject ample time to decide about participation
排除标准
- •There are no exclusion criteria for this extension study.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus - Protégé ExtensioEUCTR2008-008432-82-CZMacroGenics, Inc.538
进行中（未招募）
不适用
A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus - Protégé ExtensioRecent-onset type 1 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2008-008432-82-SEMacroGenics, Inc.538
进行中（未招募）
不适用
A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus - Protégé ExtensioEUCTR2008-008432-82-EEMacroGenics, Inc.538
进行中（未招募）
1 期
A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus - Protégé ExtensioEUCTR2008-008432-82-DEMacroGenics, Inc.538
进行中（未招募）
不适用
A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus - Protégé ExtensioRecent-onset type 1 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2008-008432-82-LVMacroGenics, Inc.538